Authorized purpose: Koios DS is an artificial intelligence (AI)/machine learning (ML)-based computer-aided diagnosis (CADx) software device intended for use as an adjunct to diagnostic ultrasound examinations of lesions or nodules suspicious for breast or thyroid cancer. Koios DS allows the user to select or confirm regions of interest (ROIs) within an image representing a single lesion or nodule to be analyzed. The software then automatically characterizes the selected image data to generate an AI/ML-derived cancer risk assessment and selects applicable lexicon-based descriptors designed to improve overall diagnostic accuracy as well as reduce interpreting physician variability. Koios DS may also be used as an image viewer of multi-modality digital images, including ultrasound and mammography. The software includes tools that allow users to adjust, measure and document images, and output into a structured report. Koios DS software is designed to assist trained interpreting physicians in analyzing the breast ultrasound images of adult (>= 22 years) female patients with soft tissue breast lesions and/or thyroid ultrasounds of all adult (>= 22 years) patients with thyroid nodules suspicious for cancer. When utilized by an interpreting physician who has completed the prescribed training, this device provides information that may be useful in recommending appropriate clinical management. Limitations: Patient management decisions should not be made solely on the results of the Koios DS analysis. Koios DS software is not to be used for the evaluation of normal tissue, on sites of post-surgical excision, or images with doppler, elastography, or other overlays present in them. Koios DS software is not intended for use on portable handheld devices (e.g. smartphones or tablets) or as a primary diagnostic viewer of mammography images. The software does not predict the presence of the thyroid nodule margin descriptor, extra-thyroidal extension. In the event that this condition is present, the user may select this category manually from the margin descriptor list.
Clinical role
Adjunct CADx: user selects or confirms ROIs of a breast lesion or thyroid nodule on ultrasound; software returns an AI/ML cancer risk assessment and lexicon-based descriptors as concurrent read and report input, addable to the DICOM series or draft report.
Images and patients
Ultrasound · Breast
Key limitation
Keep in mind: Patient management decisions should not be made solely on the results of the Koios DS analysis. Koios DS is not for normal tissue, post-surgical excision sites, or images with doppler, elastography, or other overlays; it is not intended for portable handheld devices or as a primary diagnostic viewer of mammography images; and it does not predict the thyroid nodule margin descriptor extra-thyroidal extension.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Koios DS is an artificial intelligence (AI)/machine learning (ML)-based computer-aided diagnosis (CADx) software device intended for use as an adjunct to diagnostic ultrasound examinations of lesions or nodules suspicious for breast or thyroid cancer. Koios DS allows the user to select or confirm regions of interest (ROIs) within an image representing a single lesion or nodule to be analyzed. The software then automatically characterizes the selected image data to generate an AI/ML-derived cancer risk assessment and selects applicable lexicon-based descriptors designed to improve overall diagnostic accuracy as well as reduce interpreting physician variability. Koios DS may also be used as an image viewer of multi-modality digital images, including ultrasound and mammography. The software includes tools that allow users to adjust, measure and document images, and output into a structured report. Koios DS software is designed to assist trained interpreting physicians in analyzing the breast ultrasound images of adult (>= 22 years) female patients with soft tissue breast lesions and/or thyroid ultrasounds of all adult (>= 22 years) patients with thyroid nodules suspicious for cancer. When utilized by an interpreting physician who has completed the prescribed training, this device provides information that may be useful in recommending appropriate clinical management. Limitations: Patient management decisions should not be made solely on the results of the Koios DS analysis. Koios DS software is not to be used for the evaluation of normal tissue, on sites of post-surgical excision, or images with doppler, elastography, or other overlays present in them. Koios DS software is not intended for use on portable handheld devices (e.g. smartphones or tablets) or as a primary diagnostic viewer of mammography images. The software does not predict the presence of the thyroid nodule margin descriptor, extra-thyroidal extension. In the event that this condition is present, the user may select this category manually from the margin descriptor list.
Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Breast Input: Medical images provided in a DICOM format; selected breast or thyroid ultrasound images are processed after the user selects or confirms regions of interest.
Who uses it?Intended users: Physician
What does the software produce?Output: Koios DS Breast provides categorical and continuous outputs aligned to BI-RADS and U1-U5 with auto-classified shape and orientation. Koios DS Thyroid automatically classifies thyroid nodules with output aligned to TI-RADS or ATA, generates user-modifiable nodule descriptors, and provides a direct image-derived cancer risk assessment translated into an optional lexicon-specific modifier.
What is its most important limitation?Key limitation: Patient management decisions should not be made solely on the results of the Koios DS analysis. Koios DS is not for normal tissue, post-surgical excision sites, or images with doppler, elastography, or other overlays; it is not intended for portable handheld devices or as a primary diagnostic viewer of mammography images; and it does not predict the thyroid nodule margin descriptor extra-thyroidal extension.
Clinical takeaway. Clinical role: Koios DS is an artificial intelligence (AI)/machine learning (ML)-based computer-aided diagnosis (CADx) software device intended for use as an adjunct to diagnostic ultrasound examinations of lesions or nodules suspicious for breast or thyroid cancer. Koios DS allows the user to select or confirm regions of interest (ROIs) within an image representing a single lesion or nodule to be analyzed. The software then automatically characterizes the selected image data to generate an AI/ML-derived cancer risk assessment and selects applicable lexicon-based descriptors designed to improve overall diagnostic accuracy as well as reduce interpreting physician variability. Koios DS may also be used as an image viewer of multi-modality digital images, including ultrasound and mammography. The software includes tools that allow users to adjust, measure and document images, and output into a structured report. Koios DS software is designed to assist trained interpreting physicians in analyzing the breast ultrasound images of adult (>= 22 years) female patients with soft tissue breast lesions and/or thyroid ultrasounds of all adult (>= 22 years) patients with thyroid nodules suspicious for cancer. When utilized by an interpreting physician who has completed the prescribed training, this device provides information that may be useful in recommending appropriate clinical management. Limitations: Patient management decisions should not be made solely on the results of the Koios DS analysis. Koios DS software is not to be used for the evaluation of normal tissue, on sites of post-surgical excision, or images with doppler, elastography, or other overlays present in them. Koios DS software is not intended for use on portable handheld devices (e.g. smartphones or tablets) or as a primary diagnostic viewer of mammography images. The software does not predict the presence of the thyroid nodule margin descriptor, extra-thyroidal extension. In the event that this condition is present, the user may select this category manually from the margin descriptor list.
Evidence takeaway. Evidence from the reviewed source record: The breast and thyroid engine validation sets are composed of 900 lesions from 900 different patients and 650 lesions from 650 different patients, respectively, and each was set aside from the systems' training data. The number of interpreting physicians utilized in both studies was 15 readers.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Koios DS is an artificial intelligence (AI)/machine learning (ML)-based computer-aided diagnosis (CADx) software device intended for use as an adjunct to diagnostic ultrasound examinations of lesions or nodules suspicious for breast or thyroid cancer. Koios DS allows the user to select or confirm regions of interest (ROIs) within an image representing a single lesion or nodule to be analyzed. The software then automatically characterizes the selected image data to generate an AI/ML-derived cancer risk assessment and selects applicable lexicon-based descriptors designed to improve overall diagnostic accuracy as well as reduce interpreting physician variability. Koios DS may also be used as an image viewer of multi-modality digital images, including ultrasound and mammography. The software includes tools that allow users to adjust, measure and document images, and output into a structured report. Koios DS software is designed to assist trained interpreting physicians in analyzing the breast ultrasound images of adult (>= 22 years) female patients with soft tissue breast lesions and/or thyroid ultrasounds of all adult (>= 22 years) patients with thyroid nodules suspicious for cancer. When utilized by an interpreting physician who has completed the prescribed training, this device provides information that may be useful in recommending appropriate clinical management. Limitations: Patient management decisions should not be made solely on the results of the Koios DS analysis. Koios DS software is not to be used for the evaluation of normal tissue, on sites of post-surgical excision, or images with doppler, elastography, or other overlays present in them. Koios DS software is not intended for use on portable handheld devices (e.g. smartphones or tablets) or as a primary diagnostic viewer of mammography images. The software does not predict the presence of the thyroid nodule margin descriptor, extra-thyroidal extension. In the event that this condition is present, the user may select this category manually from the margin descriptor list.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
Adjunct CADx: user selects or confirms ROIs of a breast lesion or thyroid nodule on ultrasound; software returns an AI/ML cancer risk assessment and lexicon-based descriptors as concurrent read and report input, addable to the DICOM series or draft report.
Exact FDA submission
Checked 2026-11-14
Packet wording: "computer-aided diagnosis (CADx) software device intended for use as an adjunct to diagnostic ultrasound examinations of lesions or nodules suspicious for breast or thyroid cancer." … "allows the user to select or confirm regions of interest (ROIs) within an image representing a single lesion or nodule to be analyzed. The software then automatically characterizes the selected image data to generate an AI/ML-derived cancer risk assessment and selects applicable lexicon-based descriptors". Read from the exact FDA decision document on 2026-11-14.
Medical images provided in a DICOM format; selected breast or thyroid ultrasound images are processed after the user selects or confirms regions of interest.
Exact FDA submission
Checked 2026-09-19
The packet states DICOM medical-image input and user-selected or confirmed regions for breast or thyroid ultrasound; the current value is incomplete.
Koios DS Breast provides categorical and continuous outputs aligned to BI-RADS and U1-U5 with auto-classified shape and orientation. Koios DS Thyroid automatically classifies thyroid nodules with output aligned to TI-RADS or ATA, generates user-modifiable nodule descriptors, and provides a direct image-derived cancer risk assessment translated into an optional lexicon-specific modifier.
Exact FDA submission
Checked 2026-09-19
The exact packet describes both breast and thyroid outputs; the current value covers only the thyroid output and is sourced from a non-FDA model card.
Patient management decisions should not be made solely on the results of the Koios DS analysis. Koios DS is not for normal tissue, post-surgical excision sites, or images with doppler, elastography, or other overlays; it is not intended for portable handheld devices or as a primary diagnostic viewer of mammography images; and it does not predict the thyroid nodule margin descriptor extra-thyroidal extension.
Exact FDA submission
Checked 2026-09-19
The current limitations value only says 'Scanner manufacturers: All'; this replacement uses the packet's explicit labeled limitations.
The breast and thyroid engine validation sets are composed of 900 lesions from 900 different patients and 650 lesions from 650 different patients, respectively, and each was set aside from the systems' training data. The number of interpreting physicians utilized in both studies was 15 readers.
Exact FDA submission
Checked 2026-09-19
The exact packet supports these validation-set and reader facts; the current reader-study metadata includes an unsupported null reference-standard field and does not state the packet's validation description.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The breast and thyroid engine validation sets are composed of 900 lesions from 900 different patients and 650 lesions from 650 different patients, respectively, and each was set aside from the systems' training data. The number of interpreting physicians utilized in both studies was 15 readers.
FDA source
Exact FDA submission
Checked 2026-09-19
The exact packet supports these validation-set and reader facts; the current reader-study metadata includes an unsupported null reference-standard field and does not state the packet's validation description.
Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.
Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Koios DS- Thyroid regulatory performance study summary
DesignReader Study
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K212616
IndependenceIndependence not established
K212616
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K212616. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Medical images provided in a DICOM format; selected breast or thyroid ultrasound images are processed after the user selects or confirms regions of interest.
Scope: Exact FDA submission. The packet states DICOM medical-image input and user-selected or confirmed regions for breast or thyroid ultrasound; the current value is incomplete.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes Koios DS querying and accepting DICOM compliant files from compliant devices, and saving or transferring results by in-transit transmission, saving to PACS, or exporting to third-party reporting software. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "It is a platform-agnostic web application that queries and accepts DICOM compliant digital medical files from any compliant device subject to the specified DICOM Conformance Statement for Koios DS." … "Koios DS results can be saved or transferred in three separate ways: in-transit transmission, saving to Picture Archiving and Communication System (PACS), and exporting results to third-party reporting software.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Koios DS as an ASP.NET web application deployed to a Microsoft IIS web server inside a Windows operating system environment and accessed by a user through a compatible client. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Koios DS is an ASP.NET web application deployed to a Microsoft IIS web server inside a Windows operating system environment accessed by a user through a compatible client.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Koios DS Breast provides categorical and continuous outputs aligned to BI-RADS and U1-U5 with auto-classified shape and orientation. Koios DS Thyroid automatically classifies thyroid nodules with output aligned to TI-RADS or ATA, generates user-modifiable nodule descriptors, and provides a direct image-derived cancer risk assessment translated into an optional lexicon-specific modifier.
Scope: Exact FDA submission. The exact packet describes both breast and thyroid outputs; the current value covers only the thyroid output and is sourced from a non-FDA model card.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Koios DS Breast provides categorical and continuous outputs aligned to BI-RADS and U1-U5 with auto-classified shape and orientation. Koios DS Thyroid automatically classifies thyroid nodules with output aligned to TI-RADS or ATA, generates user-modifiable nodule descriptors, and provides a direct image-derived cancer risk assessment translated into an optional lexicon-specific modifier.
Scope: Exact FDA submission. The exact packet describes both breast and thyroid outputs; the current value covers only the thyroid output and is sourced from a non-FDA model card.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Koios DS as an ASP.NET web application deployed to a Microsoft IIS web server inside a Windows operating system environment and accessed by a user through a compatible client. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Koios DS is an ASP.NET web application deployed to a Microsoft IIS web server inside a Windows operating system environment accessed by a user through a compatible client.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact FDA package describes Koios DS querying and accepting DICOM compliant files from compliant devices, and saving or transferring results by in-transit transmission, saving to PACS, or exporting to third-party reporting software. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "It is a platform-agnostic web application that queries and accepts DICOM compliant digital medical files from any compliant device subject to the specified DICOM Conformance Statement for Koios DS." … "Koios DS results can be saved or transferred in three separate ways: in-transit transmission, saving to Picture Archiving and Communication System (PACS), and exporting results to third-party reporting software.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
The exact indications cover lesions or nodules suspicious for breast or thyroid cancer; the current anatomy value retains only breast. Controlled directory display reconciled from exact FDA wording: Breast and thyroid. -> Breast.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
10Source classes checked
14Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 14 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 14 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K212616 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Koios Decision Support (DS) is an artificial intelligence (AI)/machine learning (ML)-based computer-aided diagnosis (CADx) software device intended for use as an adjunct to diagnostic ultrasound examinations of lesions or nodules suspicious for breast or thyroid cancer. Koios DS allows the user to select or confirm regions of interest (ROIs) within an image representing a single lesion or nodule to be analyzed. The software then automatically characterizes the selected image data to generate an AI/MLderived cancer risk assessment and selects applicable lexicon-based descriptors designed to improve overall diagnostic accuracy as well as reduce interpreting physician variability. Koios DS software may also be used as an image viewer of multi-modality digital images, including ultrasound and mammography. The software includes tools that allow users to adjust, measure and document images, and output into a structured report. Koios DS software is designed to assist trained interpreting physicians in analyzing the breast ultrasound images of adult (>= 22 years) female patients with soft tissue breast lesions and/or thyroid ultrasounds of all adult (>= 22 years) patients with thyroid nodules suspicious for cancer. When utilized by an interpreting physician who has completed the prescribed training, this device provides information that may be useful in recommending appropriate clinical management.
ClearView cCAD is a software application designed to assist skilled physicians in analyzing breast ultrasound images. It automatically classifies shape and orientation characteristics of user-selected regions of interest. this device uses multivariate pattern recognition methods to perform characterization and classification of images.
Authorized purpose: FETOLY analyzes fetal ultrasound images and sequences to detect labeled fetal brain and heart views, assess image completeness or quality, and provide fetal biometric measurements during the second and third trimesters.
Authorized purpose: Detect standard fetal biometry views and assist fetal biometry measurements during prenatal ultrasound acquisition and interpretation.
Modality
Ultrasound
Anatomy
Fetal biometry views and structures: cephalic/head, abdomen, and femur
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.